Morocco has roughly 38 million people and sits between Europe, sub-Saharan Africa, and the Middle East. The morocco healthcare system has changed substantially over the past five years: universal insurance coverage went from 42 to 88 percent, several large hospitals are under construction, and the government has committed to digitising patient records nationwide. For pharmaceutical companies, CROs, and global health organisations evaluating North African markets, Morocco is worth attention for its regulatory stability, growing clinical research infrastructure, and a pharmaceutical manufacturing base that already exports to more than 70 countries.
This article covers the structure of healthcare in Morocco, the AMO insurance expansion, disease burden, pharma manufacturing capacity, and the state of digital health and clinical research.
Morocco's Healthcare System at a Glance
Morocco's health sector operates under the Ministry of Health and Social Protection, which sets national health policy, manages public hospitals, and oversees pharmaceutical regulation. The system blends public provision with a significant private sector, particularly in urban areas along the Casablanca-Rabat corridor. The legislative backbone is a package of five laws adopted in 2022-2023, led by Framework Law 06-22, which reorganises the entire health system around four pillars: governance, workforce development, care delivery, and digitisation. The New Development Model 2035 sets the longer-term target of cutting out-of-pocket health spending to 30 percent and raising health workforce density to 4.5 per 1,000 inhabitants.
Government health spending has increased sharply in recent years. The health budget grew from MAD 19.7 billion (roughly $1.9 billion) in 2021 to MAD 32.6 billion (approximately $3.2 billion) projected for 2025, a 65 percent increase over four years. Total health expenditure stands at about 5.7 percent of GDP. Despite this growth, out-of-pocket spending remains high by regional standards, a pattern common across North Africa and one that Egypt's healthcare system faces as well.
Life expectancy at birth has risen to approximately 77 years for women, and neonatal mortality fell 61 percent between 2000 and 2021, from 28.4 to 11.1 deaths per 1,000 live births. Maternal deaths fell 71 percent over the same period, at an annual average reduction rate of 5.9 percent.
Health Coverage Reform: AMO and Universal Insurance
The biggest reform in Moroccan health over the past decade is the expansion of Assurance Maladie Obligatoire (AMO), the mandatory health insurance scheme. Before the reform began, only about 42 percent of the population had any form of health coverage. By the end of 2025, that figure reached 88 percent, covering more than 32 million people.
The system now operates through several channels:
- AMO Tadamon covers approximately 11 million beneficiaries from low-income households, replacing the older RAMED programme
- AMO for self-employed workers reaches about four million people, bringing informal-sector workers into the insurance system for the first time
- AMO Chaamil, a voluntary scheme, covers over 313,000 individuals
- Standard AMO covers formal-sector employees and civil servants through employer contributions
In 2025, the government adopted Law No. 02.24 to consolidate management of all basic health insurance schemes under the National Social Security Fund (CNSS), replacing the previous fragmented approach where multiple agencies administered different segments. The law also raised the dependent age limit from 26 to 30, keeping more young adults covered under family plans.
The transition is not complete. In 2026, management of public-sector AMO will shift from CNOPS to CNSS, finalising the move toward unified governance. Authorities are also updating national reference pricing and treatment protocols to control costs. Going from 42 to 88 percent coverage in under five years is fast by any standard. Most African countries are still below 10 percent insurance coverage, and in Nigeria out-of-pocket spending exceeds 70 percent of total health expenditure.
Public and Private Healthcare Infrastructure
Morocco's healthcare delivery splits between a public hospital network and a growing private sector, with significant geographic concentration in the northwest.
Public healthcare runs through 164 hospitals with roughly 10 beds per 10,000 inhabitants and more than 15,200 physicians. The military operates a parallel system with six hospitals and a medical centre. Major infrastructure projects are underway, including new hospitals in Laayoune (500 beds), Errachidia (500 beds), Beni Mellal (520 beds), and Guelmim (300 beds), plus the complete reconstruction of Rabat's Ibn Sina University Hospital with 1,044 beds.
Private healthcare includes more than 400 clinics with over 15,500 beds and 15,800 physicians. These facilities are heavily concentrated in the Casablanca-Settat and Rabat-Sale-Kenitra regions. Private providers tend to offer shorter wait times, newer equipment, and, critically for research purposes, better electronic record-keeping.
The physician ratio stands at approximately 7.8 per 10,000 inhabitants, well below the WHO-recommended minimum of 23 per 10,000. Around 270 rural municipalities are classified as being in critical medical isolation, located more than an hour from the nearest hospital. This urban-rural gap runs through most of healthcare in Morocco, and the government is trying to close it through new facility construction and telemedicine.
Disease Burden and Health Outcomes
Morocco has largely completed its epidemiological transition. Non-communicable diseases (NCDs) now account for 80 percent of all deaths, with cardiovascular disease alone responsible for 38 percent, followed by cancer at 18 percent and chronic respiratory diseases at 6 percent.
The NCD risk factor profile is significant:
- Hypertension prevalence among adults is approximately 29 percent
- Diabetes prevalence ranges from 7 to 13 percent depending on the study, with an additional 10 percent of the population classified as pre-diabetic
- Overweight and obesity affect 53 percent and 20 percent of the adult population respectively
- Physical inactivity affects about 21 percent of adults
Between 2007 and 2017, diabetes mortality rose from the ninth to the fourth leading cause of death, a 35 percent increase. Ischemic heart disease and stroke have consistently ranked as the top two causes of mortality. Four conditions alone, end-stage kidney disease, cancer, severe hypertension, and diabetes, consume over 73 percent of spending on long-term illness management.
Infectious diseases have declined substantially but are not eliminated. Morocco achieved WHO-verified elimination of malaria in 2010, and tuberculosis incidence has fallen steadily, though the country still reports cases. The disease profile looks more like a middle-income Mediterranean country than a sub-Saharan African one, which affects what types of clinical research make sense here.
Pharmaceutical Manufacturing and Export Hub
Morocco is Africa's second-largest pharmaceutical manufacturer by turnover, behind South Africa. The sector is a strategic priority for the government, and its growth has accelerated in recent years.
The pharmaceutical industry employs tens of thousands of workers and includes more than 50 manufacturing facilities. In 2023, sector turnover exceeded MAD 21 billion, a 50 percent increase over the previous year. Local production covers approximately 65 percent of domestic pharmaceutical demand, with about 10 percent of output exported to more than 70 countries.
Key players include:
- Sothema, listed on the Casablanca Stock Exchange, with a portfolio of over 300 products and partnerships with more than 35 international firms
- Cooper Pharma, which manufactures over 200 specialities and signed a cooperation agreement with China's Jemincare Pharmaceutical Group in 2025 to co-develop advanced therapeutics
- Laprophan, focused on generics, exporting to more than 30 countries and building a 92,000 square metre facility designed to meet FDA and EMA standards
- Hikma Pharmaceuticals, preparing to launch a sterile injectable facility in Casablanca by the end of 2025
Morocco is building itself into a centre for generic drug manufacturing, and its proximity to both European and West African markets gives it a logistical edge. For pharma companies and data platforms like Kapsule that track prescribing patterns and treatment outcomes, Morocco's manufacturing base makes it a natural market for real-world evidence studies on generic drug performance and therapeutic equivalence.
Digital Health Initiatives and Data Systems
Morocco's digital health agenda is moving from planning to execution. The government has committed approximately $210 million to develop a centralised medical record system, and the Ministry of Health announced several digitalisation partnerships in 2025.
Electronic health records. The ministry is implementing an integrated information system across primary healthcare facilities nationwide, enabling shared medical records and creating a unified database connecting hospitals with regional health networks. Digital health cards began replacing paper medical records in 2024, with the system sending information directly to CNSS to speed up insurance reimbursements.
Telemedicine. The National Telemedicine Initiative aims to cover 80 percent of medical deserts by 2025 and reach 1.5 million people. This is a direct response to the 270 municipalities classified as medically isolated. The Ministry of Health's Digital Development Strategy 2025 includes assisted living technology for chronic disease patients, enabling continuous remote monitoring.
Data standardisation. Morocco hosted the 2nd International e-Health Forum in October 2024 at Mohammed VI University of Health Sciences in Casablanca. Electronic health record adoption remains uneven, though. Public hospital systems and private clinics often run separate, non-interoperable platforms, a pattern similar to what many African health systems face.
As Morocco digitises records across its expanding insurance system, the volume of structured patient data will grow. Connecting this data across providers and making it available for research, with appropriate de-identification and ethics approvals, is the next step.
Clinical Research Activity and Opportunities
Morocco has an established but relatively small clinical trials ecosystem compared to South Africa or Egypt. Several CROs operate in the country, including Morocco Clinical Trials (part of the MCT Group), Clinova, and international firms like SGS and INNOVA.
The regulatory environment is stable. Morocco's pharmaceutical regulatory authority reviews trial protocols, and the country's university hospitals in Rabat, Casablanca, Fez, and Marrakech serve as the primary research sites. The Mohammed VI University of Health Sciences has emerged as a hub for health research and clinical education.
What works in Morocco's favour for clinical research: an NCD-dominated disease burden that aligns with global pharma pipelines, a large insured population generating structured encounter data through AMO, geographic proximity to Europe (Casablanca is under three hours from Paris or Madrid), French and Arabic bilingualism that facilitates collaboration with European and MENA-region sponsors, and a manufacturing base that can support local drug supply for trials.
The country's limitations are real. The physician shortage constrains the number of qualified principal investigators. Rural site activation remains difficult. And while the regulatory framework is functional, timelines for ethics committee review can be unpredictable.
For sponsors evaluating North African sites, Morocco offers a middle path: more regulatory predictability than many sub-Saharan markets, a patient population with NCD profiles that match global study designs, and an insurance system that is rapidly generating the kind of structured health data that supports site feasibility assessments and patient identification. Platforms like Kapsule, which aggregate de-identified records from facility-level systems, can help sponsors evaluate patient volumes and disease prevalence before committing to site selection.
Kapsule provides access to structured, de-identified health records from over three million patient encounters across East and West Africa, with standing ethics approvals in Rwanda, Kenya, Uganda, Nigeria, and Ghana. Contact our team to discuss how North African health data can support your clinical development and market access strategy.
This article is intended for informational purposes only and does not constitute legal, medical, or regulatory advice. Readers should obtain independent professional counsel for their specific circumstances.